Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.52 |
| ▸ | RORC | P51449 | 7/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL528345 | 0.89 | RORC (0.61) | TACR1RORCMAPTP2RY14GPR119 | |
| SCHEMBL15194668 | 0.88 | HDAC1 (0.51) | TACR1RORCGPR119PDE4B | |
| SCHEMBL4886021 | 0.87 | TACR1 (0.53) | TACR1RORCMAPTP2RY14GPR119 | |
| SCHEMBL4727085 | 0.87 | TACR1 (0.53) | TACR1RORCMAPTP2RY14GPR119 | |
| SCHEMBL528144 | 0.87 | TACR1 (0.54) | TACR1RORCMAPTGPR119STS | |
| SCHEMBL528081 | 0.86 | STS (0.50) | STSPDE4B | |
| SCHEMBL15197029 | 0.86 | STS (0.50) | STSPDE4B | |
| SCHEMBL527927 | 0.85 | TACR1 (0.53) | TACR1RORCGPR119STS | |
| SCHEMBL2247001 | 0.85 | TACR1 (0.53) | TACR1RORCGPR119STS | |
| SCHEMBL2244924 | 0.85 | TACR1 (0.53) | TACR1RORCGPR119STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105793254-B | Azaquinazoline carboxamide derivatives | 默克专利有限公司 | 2020-10-23 | — | — | CN | disclosed |
| EP-2925747-B1 | AZAQUINAZOLINE CARBOXAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-06-24 | — | — | EP | disclosed |
| US-10233160-B2 | Substituted pyrido[3,4-d]pyrimidines and pyrido[4,3-d]pyrimidines as p70S6K inhibitors | MERCK PATENT GMBH (DE) | 2019-03-19 | — | — | US | disclosed |
| US-10087166-B2 | Cyclic amine azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2018-10-02 | — | — | US | disclosed |
| US-20180237402-A1 | AZAQUINAZOLINE CARBOXAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-08-23 | — | — | US | disclosed |
| US-9981925-B2 | Substituted benzo[d][1,2,3]triazines as p70S6K inhibitors | MERCK PATENT GMBH (DE) | 2018-05-29 | — | — | US | disclosed |
| US-20170129877-A1 | Cyclic Amine Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2017-05-11 | — | — | US | disclosed |
| US-9586938-B2 | Cyclic amine azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2017-03-07 | — | — | US | disclosed |
| US-20160340323-A1 | AZAQUINAZOLINE CARBOXAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-11-24 | — | — | US | disclosed |
| US-9440968-B2 | Substituted pyrido[3,2-d]pyrimidines for treating cancer | MERCK PATENT GMBH (DE) | 2016-09-13 | — | — | US | disclosed |
| EP-2925747-A1 | AZAQUINAZOLINE CARBOXAMIDE DERIVATIVES | Merck Patent GmbH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-20150259339-A1 | AZAQUINAZOLINE CARBOXAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2014085528-A1 | AZAQUINAZOLINE CARBOXAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-06-05 | — | — | WO | disclosed |
| US-20130217709-A1 | Cyclic Amine Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| EP-2598497-A1 | CYCLIC AMINE AZAHETEROCYCLIC CARBOXAMIDES | Merck Patent GmbH (DE) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012016001-A1 | CYCLIC AMINE AZAHETEROCYCLIC CARBOXAMIDES | MERCK PATENT GMBH (DE) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259339-A1 | AZAQUINAZOLINE CARBOXAMIDE DERIVATIVES | RPS6KA3, RPS6KA4, CDK4 | TACR1 4725/4885RORC 2635/4885MAPT 4389/4885 |
| US-20130217709-A1 | Cyclic Amine Azaheterocyclic Carboxamides | MKI67, AZI2, PCNA | TACR1 3511/4885RORC 1474/4885MAPT 4466/4885 |
| US-20180237402-A1 | AZAQUINAZOLINE CARBOXAMIDE DERIVATIVES | RPS6KA3, RPS6KA4, CDK4 | TACR1 4725/4885RORC 2635/4885MAPT 4389/4885 |
| US-20170129877-A1 | Cyclic Amine Azaheterocyclic Carboxamides | MKI67, AZI2, PCNA | TACR1 3511/4885RORC 1474/4885MAPT 4466/4885 |
| US-20160340323-A1 | AZAQUINAZOLINE CARBOXAMIDE DERIVATIVES | RPS6KA3, RPS6KA4, CDK4 | TACR1 4725/4885RORC 2635/4885MAPT 4389/4885 |
| US-10233160-B2 | Substituted pyrido[3,4-d]pyrimidines and pyrido[4,3-d]pyrimidines as p70S6K inhibitors | CDK4, CDK2, RPS6KA4 | TACR1 4460/4885RORC 2090/4885MAPT 4095/4885 |
| US-10087166-B2 | Cyclic amine azaheterocyclic carboxamides | MKI67, AZI2, PCNA | TACR1 3511/4885RORC 1474/4885MAPT 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.